EFPIA Urges Drug Makers To See Value In Mobile Apps
This article was originally published in The Pink Sheet Daily
Executive Summary
The head of EFPIA believes drug makers are squandering opportunities offered by mobile health applications, a key point in the European trade body’s new manifesto.
You may also be interested in...
European Notebook: Industry’s Post-EU Election Goals; IMI2 Gets Under Way; FDA/EMA Tie-Up On Childhood Gaucher Studies
Worries about science bases drew European politicians to the AstraZeneca/Pfizer merger debate; the European industry calls for EU-wide R&D agenda, standards of care; IMI2 public-private partnership gets under way; FDA and EMA to collaborate on clinical trials for childhood Gaucher disease.
Public-Private Partnerships Like IMI Crucial to Industry's Future, Argue Leaders
Public-private partnerships like Europe's Innovative Medicines Initiative, the EU’s mechanism that promotes new treatment R&D, are crucial to the industry's future, according to Paul Stoffels, Chairman global R&D pharmaceuticals at Johnson & Johnson.
Proposal To Improve Patient Information Attracts More EU Support
Pharma is relieved as an EU parliamentary committee approves revised information-to-patients proposals